FDA accelerated approval for talquetamab-tgvs in multiple myeloma
The agency's approval, granted August 9, 2023, covers relapsed or refractory multiple myeloma patients under the brand name Talvey.
The Food and Drug Administration granted accelerated approval to talquetamab-tgvs, marketed as Talvey by Janssen Biotech, Inc., for patients with relapsed or refractory multiple myeloma. On August 9, 2023, the Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.)1
The source record provided does not include further details on the specific trial data, dosing regimen, or endpoint results that supported this approval, nor does it specify confirmatory trial requirements typically associated with accelerated approvals. Readers seeking those specifics should consult the full FDA approval documentation or the prescribing information for Talvey.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.